Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

This study investigates whether adding nicotinamide riboside (NR) — a form of vitamin B3 — as a supplement before and after a bone marrow transplant (allogeneic haematopoietic cell transplantation or alloHCT) can reduce transplant-related complications and improve recovery. NR supports cellular energy production, and early research suggests it may help protect organs and support immune recovery in the period following transplant. The study focuses on patients with blood cancers and blood disorders (excluding myelofibrosis) who are undergoing a myeloablative (intensive conditioning) bone marrow transplant from a matched donor. You may be eligible if: - You are 18 years or older - You are scheduled for a myeloablative allogeneic bone marrow transplant for a qualifying condition - You have a suitable HLA-matched related or unrelated donor You may NOT be eligible if: - You have myelofibrosis - You have an allergy or intolerance to NR, niacin, or nicotinamide - You are pregnant or breastfeeding - You have an uncontrolled illness or psychiatric condition affecting compliance Talk to your doctor to see if this trial is right for you.